Quick Answer
Viking Therapeutics, Inc. reported Total Revenue of $0.00 for fiscal year 2025.
Viking Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue (ASC 606) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$359.64M -227.1% |
-$109.96M -28.0% |
-$85.89M -24.7% |
-$68.87M -25.2% |
-$54.99M -39.2% |
-$39.49M -53.2% |
| Diluted EPS | -$3.19 -215.8% |
-$1.01 -11.0% |
-$0.91 -1.1% |
-$0.90 -26.8% |
-$0.71 | — |
| Total Assets | $715.73M -21.2% |
$908.32M +146.5% |
$368.49M +118.7% |
$168.53M -20.0% |
$210.66M -17.9% |
$256.50M -9.8% |
| Cash and Equivalents | $165.81M +521.6% |
$26.68M -51.9% |
$55.52M +51.6% |
$36.63M +38.9% |
$26.37M -9.4% |
$29.12M +247.6% |
| Stockholders Equity | $639.06M -27.4% |
$880.28M +152.6% |
$348.42M +139.8% |
$145.32M -28.0% |
$201.88M -17.4% |
$244.34M -11.8% |
| R&D Expense | $344.95M +239.4% |
$101.64M +59.3% |
$63.81M +17.6% |
$54.23M +20.6% |
$44.98M +40.9% |
$31.93M +35.5% |
| Operating Income | -$393.34M -160.6% |
-$150.92M -49.7% |
-$100.83M -43.3% |
-$70.36M -26.4% |
-$55.68M -30.5% |
-$42.66M -30.5% |
| Shares Outstanding | 114.79M +2.9% |
111.57M +11.4% |
100.11M +27.9% |
78.26M +0.0% |
78.25M +6.9% |
73.22M +1.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $0.00 | — | — |
| Revenue (ASC 606) | September 30, 2025 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$90.79M | -264.0% | -38.5% |
| Diluted EPS | September 30, 2025 | -$0.81 | -268.2% | -39.7% |
| Total Assets | September 30, 2025 | $739.41M | -21.2% | -10.7% |
| Cash and Equivalents | September 30, 2025 | $100.38M | +99.4% | +196.3% |
| Stockholders Equity | September 30, 2025 | $713.03M | -21.8% | -10.4% |
| R&D Expense | September 30, 2025 | $89.95M | +294.8% | +49.5% |
| Operating Income | September 30, 2025 | -$98.56M | -169.6% | -32.2% |
| Shares Outstanding | September 30, 2025 | 112.45M | +0.9% | +0.1% |
- Viking Therapeutics, Inc. reported Total Revenue of $0.00 for fiscal year 2025.
- Viking Therapeutics, Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2025.
- Viking Therapeutics, Inc. reported Net Income of -$359.64 million for fiscal year 2025.
- Viking Therapeutics, Inc. showed a decrease of -227.1% in Net Income compared to the prior fiscal year.
- Viking Therapeutics, Inc. reported Diluted EPS of $3.19 per share (loss) for fiscal year 2025.
- Viking Therapeutics, Inc. showed a decrease of -215.8% in Diluted EPS compared to the prior fiscal year.
- Viking Therapeutics, Inc. reported Total Assets of $715.73 million for fiscal year 2025.
- Viking Therapeutics, Inc. showed a decrease of -21.2% in Total Assets compared to the prior fiscal year.
- Viking Therapeutics, Inc. reported Cash and Equivalents of $165.81 million for fiscal year 2025.
- Viking Therapeutics, Inc. showed an increase of +521.6% in Cash and Equivalents compared to the prior fiscal year.
- Viking Therapeutics, Inc. reported Stockholders Equity of $639.06 million for fiscal year 2025.
- Viking Therapeutics, Inc. showed a decrease of -27.4% in Stockholders Equity compared to the prior fiscal year.
- Viking Therapeutics, Inc. reported R&D Expense of $344.95 million for fiscal year 2025.
- Viking Therapeutics, Inc. showed an increase of +239.4% in R&D Expense compared to the prior fiscal year.
- Viking Therapeutics, Inc. reported Operating Income of -$393.34 million for fiscal year 2025.
- Viking Therapeutics, Inc. showed a decrease of -160.6% in Operating Income compared to the prior fiscal year.
- Viking Therapeutics, Inc. reported Shares Outstanding of 114.79 million shares for fiscal year 2025.
- Viking Therapeutics, Inc. showed an increase of +2.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: